SOCM
ORIC icon

SR One Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

SR One Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.5M Hold
4,514,929
– – 6.39% 6
2025
Q4 		$37.8M Hold
4,514,929
– – 5.34% 7
2025
Q3 		$54.2M Hold
4,514,929
– – 7.84% 5
2025
Q2 		$45.8M Buy
+4,514,929
New +$30.3M 9.93% 5

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SR One Capital Management's ORIC Position: Q1 2026 in Review

SR One Capital Management held its Oric Pharmaceuticals (ORIC) position steady in Q1 2026 at 4,514,929 shares worth $58.5M. The position accounts for 6.39% of the portfolio, ranked #6.

SR One Capital Management first reported a position in ORIC in Q2 2025 and has held it in 4 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • SR One Capital Management held 4,514,929 shares of Oric Pharmaceuticals worth $58.5M as of Q1 2026.
  • SR One Capital Management left its Oric Pharmaceuticals share count unchanged in Q1 2026.
  • Oric Pharmaceuticals made up 6.39% of SR One Capital Management's portfolio in Q1 2026, its #6 holding.
  • SR One Capital Management first reported a position in Oric Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on SR One Capital Management's 13F filing for Q1 2026, filed 14 May 2026.